The central premise of this resubmitted, competitive renewal R01 application is to understand the biology of disease in Spinocerebellar Ataxia Type 3 (SCA3), the most common dominant ataxia worldwide. SCA3 is caused by abnormal CAG triplet repeat expansion in the gene ATXN3, which translates into a long polyglutamine (polyQ) tract in the deubiquitinase ataxin-3. How SCA3 occurs remains unresolved; this disease is uniformly fatal in patients. SCA3 belongs to the family of polyQ diseases, which includes another eight disorders. In each disease, the primary culprit of neuronal toxicity is the glutamine repeat within the primary sequence of its causative protein. PolyQ expansion beyond normal ranges leads to protein misfolding, neuronal dysfunction and death. There is clear evidence that the manner in which polyQ toxicity presents? CNS areas impacted and cellular processes perturbed?is regulated by peptide regions outside of the polyQ tract, what is commonly referred to as protein context. This fundamental aspect of polyQ degeneration is underscored by the fact that although a similar mutation causes each disease, the symptoms presented and the nervous system areas impacted differ among them. To understand the biology of polyQ diseases, we need to comprehend how the protein areas around each polyQ region control and modulate the toxicity of the expanded repeat. Our focus in this competitive renewal application is to systematically understand the role of protein context in SCA3. Our over-arching hypothesis is that pathogenicity conferred onto ataxin-3 by abnormal polyQ tract expansion is controlled by specific binding partners at this protein's non-polyQ domains. Our work during the prior cycle of this R01 award provided key clues about the role of protein context in SCA3. We found that two of its non-polyQ regions exert significant modulatory effect on degeneration caused by ataxin-3 in vivo. One region controls the interaction of ataxin-3 with the proteasome-associated protein Rad23; the other is used by the SCA3 protein to directly bind to the AAA ATPase VCP/p97. Each interaction has a specific and clear effect on the toxicity of pathogenic ataxin-3. In this cycle, we seek to expand on our findings and to propel our work through novel models and approaches. We propose a systematic and interdisciplinary set of studies to define the role of non-polyQ domains on the aggregation, toxicity and cellular properties of pathogenic ataxin-3 in vivo, while also investigating more broadly the cellular response to this toxic protein. We are confident that our work will add much needed perspective to the role of protein context in SCA3 from complementary and progressively wider angles, establish novel tools to study this disease, and provide new conceptual advances that will likely inform the biology of other proteotoxic disorders.

Public Health Relevance

Age-dependent neurodegeneration is a major health issue that will worsen as people live longer lives. Mechanisms of neurodegeneration and protective pathways to combat disease are poorly understood. We propose to elucidate the function of specific proteins and cellular pathways that can be used to provide protection from degenerative processes, with special emphasis on Spinocerebellar Ataxia Type 3, the most common dominant ataxia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS086778-06A1
Application #
9811467
Study Section
Cellular and Molecular Biology of Neurodegeneration Study Section (CMND)
Program Officer
Miller, Daniel L
Project Start
2014-04-01
Project End
2023-02-28
Budget Start
2019-06-15
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wayne State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Nath, Samir R; Yu, Zhigang; Gipson, Theresa A et al. (2018) Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction. J Clin Invest 128:3630-3641
Blount, Jessica R; Libohova, Kozeta; Marsh, Gregory B et al. (2018) Expression and Regulation of Deubiquitinase-Resistant, Unanchored Ubiquitin Chains in Drosophila. Sci Rep 8:8513
Murray, Andrew S; Varela, Fausto A; Hyland, Thomas E et al. (2017) Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization. J Biol Chem 292:14867-14884
Sutton, Joanna R; Blount, Jessica R; Libohova, Kozeta et al. (2017) Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. Hum Mol Genet 26:1419-1431
Das, Banibrata; Rajagopalan, Subramanian; Joshi, Gnanada S et al. (2017) A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses ?-syn- and MPTP-induced toxicities in vivo. Neuropharmacology 123:88-99
Ristic, Gorica; Tsou, Wei-Ling; Guzi, Ermal et al. (2016) USP5 Is Dispensable for Monoubiquitin Maintenance in Drosophila. J Biol Chem 291:9161-72
Tsou, Wei-Ling; Qiblawi, Sultan H; Hosking, Ryan R et al. (2016) Polyglutamine length-dependent toxicity from ?1ACT in Drosophila models of spinocerebellar ataxia type 6. Biol Open 5:1770-1775
Costa, Maria do Carmo; Ashraf, Naila S; Fischer, Svetlana et al. (2016) Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain 139:2891-2908
Yedlapudi, Deepthi; Joshi, Gnanada S; Luo, Dan et al. (2016) Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep 6:38510
Tsou, Wei-Ling; Ouyang, Michelle; Hosking, Ryan R et al. (2015) The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster. Neurobiol Dis 82:12-21

Showing the most recent 10 out of 14 publications